Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
ROCKVILLE, Md., March 06, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that Kenneth T. Mills, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, REGENXBIO representatives will be holding one-on-one meetings at the conference.
A live webcast of the presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
